Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stocks were rallying late Friday afternoon after a choppy morning, as investors appeared to shrug off fears of New York's first Ebola case, concentrating instead on stronger-than-expected housing data and quarterly earnings.
Canadian biopharmaceuticals firm Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) jumped in early deals Wednesday after the company said it has begun limited manufacturing of a new therapeutic targeting the Ebola-Guinea virus, which is the viral variant responsible for the current epidemic in West Africa.
Tekmira's (NASDAQ:TKMR) (TSE:TKM) shares have been rising this week ever since the first US case of Ebola emerged in Texas, and are up another 8 percent today after announcing a $1.5 million milestone payment from agricultural giant Monsanto (NYSE:MON).
OrganiGram (CVE:OGI) is currently one of 13 licensed producers for medical marijuana so far in Canada under the government’s new regulations, but the company is the only provider east of Ontario and one of two producers (the sole publicly listed one) growing an organic product.
Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) extended gains on Tuesday after the company said it has taken another step to help combat the Ebola crisis by collaborating with an international consortium to provide an RNAi-based investigational drug for expedited clinical studies in West Africa.
Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) were jumping Monday afternoon after the FDA authorized the company to provide its TKM-Ebola treatment to people with confirmed or suspected Ebola infections.
Investors interested in Neuralstem recently viewed
- Amphion Innovations (LON: AMP) Amphion builds shareholder value in the medical and technology sectors
- Cellmid (ASX: CDY) Cellmid is the world leader in Midkine Intellectual Property
- Acuvax soon to be renamed Biolife Science Limited (asx: ACU) .
- OncoSil Medical Limited (ASX: OSL) New technology to provide safe radiation treatments
- Epistem Holdings Plc (AIM: EHP) Biotechnology company applying its expertise in epithelial stem cells